title: Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study.
authors.forename: Fabiola
authors.initials: F
authors.lastname: Atzeni
authors.forename: Laura
authors.initials: L
authors.lastname: Boccassini
authors.forename: Marco
authors.initials: M
authors.lastname: Antivalle
authors.forename: Fausto
authors.initials: F
authors.lastname: Salaffi
authors.forename: Piercarlo
authors.initials: P
authors.lastname: Sarzi-Puttini
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000379:methods; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D010865:Pilot Projects; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D016572:Cyclosporine; D000068800:Etanercept; D008727:Methotrexate